New Drug Combination with Radiation for Head and Neck Cancer
Treatments studied
Part of Bones, joints & muscles, Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This trial tests a combination of two new drugs (ficerafusp alfa and pembrolizumab) along with focused radiation therapy for newly diagnosed head and neck cancer that hasn't spread widely. The goal is to shrink the cancer before surgery and potentially improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Recently diagnosed head and neck squamous cell carcinoma (a type of cancer in the mouth, throat, or voice box) that is locally advanced but can be surgically removed
- Cancer must be stage III, IVA, or IVB and be HPV-negative (not caused by human papillomavirus)
- Your tumor must have a specific marker called PD-L1 (your doctor will test this)
- Age 18 or older with good overall health and ability to care for yourself (ECOG 0-1)
- Healthy organ function (normal blood counts, liver, and kidney function)
- Willingness to have blood draws and tumor biopsies (small tissue samples) before treatment and during surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining radiation therapy with immunotherapy works better than immunotherapy alone for advanced head and neck cancer that hasn't been treated before. The goal is to help your body's immune system fight the cancer more effectively.
This trial tests a new combination of two immunotherapy drugs (petosemtamab plus pembrolizumab) compared to pembrolizumab alone for people with head and neck cancer that has spread or come back and cannot be cured locally. It may be an option if your cancer has a certain protein (PD-L1) and you haven't had prior cancer treatment for this stage.
This trial is testing whether a newer type of PET/CT scan (F-18 NaF) can better detect blood vessel problems caused by radiation therapy than the standard scan (F-18 FDG) in people with head and neck cancer. If successful, it could lead to better ways to prevent and manage these complications.
This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.
This trial tests a custom treatment plan for people with advanced head and neck cancer that is not caused by HPV. It combines radiation and chemotherapy with a targeted drug called cetuximab, adjusted based on your tumor's characteristics.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.